文献速递细菌感染、耐药与抗菌药物医院感染防控

非移植患者碳青霉烯耐药肺炎克雷伯菌血流感染的危险因素与结局回顾性分析

A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
PubMed 文献 · J Infect Dis · 2020-01-01

CRKP组28天死亡率55.8%,显著高于碳青霉烯敏感组的13.9%(P < .001)。多因素分析显示既往胃管置入、碳青霉烯暴露、低蛋白血症和高APACHE II评分为CRKP血流感染的独立危险因素,而CRKP感染、重症和替加环素治疗为死亡的独立危险因素。

要点

  • 非移植患者CRKP血流感染28天死亡率55.8%,显著高于碳青霉烯敏感组的13.9%。
  • 既往碳青霉烯暴露是CRKP血流感染的独立危险因素。
  • 亚胺培南MIC >8 mg/L、替加环素治疗及不恰当治疗增加28天死亡率。

核心结论

  • 非移植患者CRKP血流感染死亡率更高,碳青霉烯暴露是CRKP感染的独立危险因素。
  • 亚胺培南MIC >8 mg/L、替加环素治疗和不恰当治疗增加KP血流感染患者28天死亡率。

主要发现

  • 371例中104例(28.0%)为CRKP。
  • CRKP组28天死亡率为55.8%,碳青霉烯敏感组为13.9%(P < .001)。
  • 多因素分析显示既往胃管置入、既往碳青霉烯使用、低蛋白血症和高APACHE II评分是CRKP血流感染的独立危险因素。
  • CRKP感染、重症和替加环素治疗是KP血流感染死亡的独立危险因素。
  • 经验性和目标性抗生素治疗不恰当以及亚胺培南MIC >8 mg/L与不良临床结局相关。

临床怎么用

  • 对非移植KP血流感染患者,应评估既往碳青霉烯暴露、胃管置入、低蛋白血症和高APACHE II评分等CRKP感染危险因素。
  • 治疗CRKP血流感染时,应关注亚胺培南MIC >8 mg/L、避免不恰当经验性治疗,并谨慎评估替加环素治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) has become a major problem among nosocomial infections, and it is a serious threat to patients. The clinical characteristics and outcome of CRKP bloodstream infection (BSI) in nontransplant patients remains unelucidated. The aim of this study was as follows: identify the risk factors of CRKP infection; generate new ideas for prevention; and generate new ideas for the most effective therapeutic management in nontransplant patients. METHODS: The study retrospectively analyzed the clinical and microbiological data of nontransplant patients with K pneumoniae (KP) bacteremia from January 2013 to December 2015 to identify risk factors, clinical features, and outcomes using multivariate logistic regression analysis. RESULTS: Of the 371 patients with KP-BSI in nontransplant patients included in this study, 28.0% (N = 104) had CRKP. The 28-day mortality was higher in patients infected with CRKP (55.8%) than in those with carbapenem-susceptible KP (13.9%) (P < .001). Multivariate analysis showed previous gastric catheterization, previous use of carbapenems, hypoproteinemia, and high Acute Physiologic Assessment and Chronic Health Evaluation II scores as independent risk factors for CRKP-BSIs. Carbapenem-resistant KP infection, severe illness, and tigecycline therapy were independent risk factors for death from KP-BSIs. Taken together, inappropriate antibiotic treatment both in empirical and definitive therapy and imipenem minimum inhibitory concentrations (MICs) of >8 mg/L were associated with poor clinical outcome. CONCLUSIONS: Nontransplant patients with CRKP-BSI had higher mortality. Carbapenems exposure was an independent risk factor for CRKP infection. Imipenem MICs of >8 mg/L, tigecycline therapy, and inappropriate treatments increased the 28-day mortality of KP-BSI patients.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Xiao T, Zhu Y, Zhang S, et al. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients. J Infect Dis. 2020. PMID: 32176799. doi:10.1093/infdis/jiz559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。